Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [3] - The company utilizes a patented SCS Microinjector for targeted and compartmentalized delivery of therapies, aiming to improve patient outcomes in sight-threatening eye diseases [3] - Clearside's lead program, CLS-AX (axitinib injectable suspension), is in development for treating neovascular age-related macular degeneration (wet AMD), with planning for a Phase 3 program underway [3] Product Development - Clearside has developed its first product, XIPERE (triamcinolone acetonide injectable suspension), which is approved for suprachoroidal use and available in the U.S. through a commercial partner [3] - The company is also evaluating various small molecules for potential long-acting treatment of geographic atrophy (GA) [3] - Clearside strategically partners its SCS injection platform with other companies utilizing ophthalmic therapeutic innovations [3] Financial Information - The company will report its first quarter 2025 financial results on May 14, 2025, after the close of financial markets [1] - There will be no conference call hosted for this quarter [1]